A Comparative Study Of Noninvasive Hypoxia Imaging With F-18-Fluoroerythronitroimidazole And F-18-Fluoromisonidazole Pet/Ct In Patients With Lung Cancer
Y. C. Wei,W. Zhao,X. Hu,Q. Yu,S. Zhu,S. Wang,J. Yu,S. Gao,S. Yuan
DOI: https://doi.org/10.1371/journal.pone.0157606
IF: 3.7
2016-01-01
PLoS ONE
Abstract:PurposeThis is a clinical study to compare noninvasive hypoxia imaging using F-18-fluoroerythronitroimidazole (F-18-FETNIM) and F-18-fluoromisonidazole (F-18-FMISO) positron emission tomography/computed tomography (PET/CT) in patients with inoperable stages III-IV lung cancer.MethodsA total of forty-two patients with inoperable stages III-IV lung cancer underwent F-18-FETNIM PET/CT (n = 18) and F-18-FMISO PET/CT (n = 24) before chemo/radiation therapy. The standard uptake values (SUVs) of malignant and normal tissues depict F-18-FETNIM PET/CT and F-18-FMISO PET/CT uptake. Tumor-to-blood ratios (T/B) were used to quantify hypoxia.ResultsAll patients with lung cancer underwent F-18-FETNIM PET/CT and F-18-FMISO PET/CT successfully. Compared to F-18-FMISO, F-18-FETNIM showed similar uptake in muscle, thyroid, spleen, pancreas, heart, lung and different uptake in blood, liver, and kidney. Significantly higher SUV and T/B ratio with F-18-FMISO (2.56 +/- 0.77, 1.98 +/- 0.54), as compared to F-18-FET-NIM (2.12 +/- 0.56, 1.42 +/- 0.33) were seen in tumor, P = 0.022, <0.001. For the patients with different histopathological subtypes, no significant difference of SUV (or T/B ratio) was observed both in F-18-FMISO and 18F-FETNIM in tumor. A significantly different SUV (or T/B ratio) was detected between < = 2cm, 2 similar to 5cm, and >5cm groups in F-18-FMISO PET/CT, P = 0.015 (or P = 0.029), whereas no difference was detected in F-18-FMISO PET/CT, P = 0.446 (or P = 0.707). Both F-18-FETNIM and F-18-FMISO showed significantly higher SUVs (or T/B ratios) in stage IV than stage III, P = 0.021, 0.013 (or P = 0.032, 0.02).ConclusionF-18-FMISO showed significantly higher uptake than 18F-FETNIM in tumor/non-tumor ratio and might be a better hypoxia tracer in lung cancer.